This is a single center prospective cohort study. The cohort (interventional) patients will receive the study intervention (ABCLO). The control group retrospective patients that were previously managed at the same center, regardless of the technique or the device used to close the OA.
This study will describe and compare the rates of asthma exacerbations observed between 12-month pre-switch and 12-month post-switch periods among participants switching to AIRSUPRA. Other outcome measures included in this study are asthma-related oral corticosteroid (OCS) use, and asthma exacerbation-related healthcare resource utilization (HCRU), healthcare cost, and patient reported outcomes (PROs).
Gore has developed and manufactures the GORE® SYNECOR Intraperitoneal Biomaterial device (GORE® SYNECOR IP Device) to offer clinicians a mesh material intended for the repair of ventral/incisional hernias that may require the addition of a nonabsorbable reinforcing or bridging material. The primary study objective is to assess SYNECOR Biomaterial performance on incisional hernia patients over an extended amount of time through multiple methods. The secondary study objective is to conduct configuration-specific assessments to address areas of medical interest.
we plan to use non invasive ADP (air displacement plethysmography) method to measure body composition in very low birth weight infants and follow their neurodevelopment using HINE (Hammersmith Infant Neurological examination)
This study aims to learn more about the investigational drug, ASTX727, and another drug, venetoclax, when given in combination. It also aims to evaluate potential pharmocokinetics (PK) interactions for the treatment of newly diagnosed acute myeloid leukemia (AML) in adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy.
The primary purpose of the study is to rule out drug-drug interactions between ASTX727 and venetoclax combination therapy.
ARCADIA is a multicenter, biomarker-driven, randomized, double-blind, active-control, phase 3 clinical trial of apixaban versus aspirin in patients who have evidence of atrial cardiopathy and a recent stroke of unknown cause. Eleven hundred subjects will be recruited over 2.5 years at 120 sites in the NIH StrokeNet consortium. Subjects will be followed for a minimum of 1.5 years and a maximum of 4 years for the primary efficacy outcome of recurrent stroke and the primary safety outcomes of symptomatic intracranial hemorrhage and major hemorrhage other than intracranial hemorrhage.
Breast cancer (BC) is the leading cause of cancer and the second most common cause of cancer related mortality in the United States. Although the prognosis of patients with BC has greatly improved over the past few years, there are still many unanswered questions. There is growing interest in identifying markers for treatment de-escalation or intensification in early and advanced breast cancer as well as in ductal carcinoma in situ (DCIS). Additionally, there are well known differences in disease biology and outcomes in groups from diverse genetic ancestry.
Broadly, the purpose of this project is to evaluate the baseline stroke and dementia risk of those Indvidual identified by NLP and characterize the population identified during the recruitment process through enrollment. Additionally, we seek to assess changes to medical care and medications in the 90-days after being informed of the NLP findings.
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard endocrine therapy in patients with ER+/HER2 - early breast cancer who completed definitive locoregional therapy (with or without chemotherapy) and standard adjuvant endocrine therapy (ET) for at least 2 years and up to 5 years. The eligible patients must have intermediate or high risk of recurrence, as defined by specified clinical and biologic criteria.
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who completed definitive locoregional therapy (with or without chemotherapy).
Patients receiving commercial CAR-T therapy for their clinical care are invited to provide 5 blood draws at the time blood is drawn for their clinical care. The samples will be used to help develop a new technology for detecting CAR-T cells in the blood.
Prospective randomized controlled trial comparing low dose Prednisone(or Prednisolone)/Methotrexate combination to standard dose Prednisone(or Prednisolone) in patients diagnosed with acute active clinically manifest cardiac sarcoidosis and not yet treated. The Investigators hypothesize that low dose Prednisone(or Prednisolone)/Methotrexate combination will be as effective as standard dose Prednisone(or Prednisolone), and result in significantly better quality of life and less toxicity than standard dose Prednisone(or Prednisolone).
Collecting and storing heart tissue and blood samples from consented Tufts Medical Center patients for the purpose of cardiovascular research.
Patients with Chronic Kidney Disease(CKD) who receive medical care at Tufts Medicine will be invited to join a CKD research registry. The registry will record their medical information related to CKD and future researchers will be allowed to contact patients to ask if they would like to join a CKD related research study. There is nothing patients have to do once they join the registry, and joining a CKD research study is entirely optional.
This is a 10-year, longitudinal, observational study of patients with PSC to address knowledge gaps in the clinical presentation, natural history, epidemiology, progression, and outcomes of PSC. In addition, the study will address prognostic models and biomarker development. There will be an option to participate in specimen repository at each site for translational studies of genomics and novel biomarkers discovery.
This clinical investigation is intended to evaluate the safety and effectiveness of Abbott’s AmplatzerTM AmuletTM Left Atrial Appendage (LAA) occluder device (“Amulet device”) compared to commercially available non-vitamin K antagonist oral anticoagulant (NOAC) drugs in patients with non-valvular atrial fibrillation (AF) who are at increased risk for ischemic stroke and who are tolerant of long-term NOAC therapy.
Patients receiving maintenence hemodialysis will be screened for underlying cognitive impairment using the Montreal Cognitive Assessment (MoCA) Tool, a cognitive screening tool. Routine dialysis data, including biochemical measures and attendance records, will then be subsequently examined. Depending on the MoCA results, patients may be invited to participate in an interview to explore their experience with the MoCA screening tool and other aspects of their dialysis care.
This Phase II/III trial will evaluate the what kind of chemotherapy to recommend to patients based on the presence or absences of circulating tumor DNA (ctDNA) after surgery for colon cancer.
This research study will investigate the independent effects of an environmental intervention (E only), an individual-level eHealth phone program intervention (I only), or both (E+I) on changes in moderate intensity physical activity. A cluster randomized design will be implemented whereby all residents of one of 12 of Boston's public housing developments (PHDs) will be randomized to one of the four study groups (E only, I only, E+I, or control). The findings will inform future health promotion efforts among residents in public housing developments
The primary goal of this study is to use the WHOOP fitness band as a way to measure heart rate variability (HRV) in patients with coronary artery disease (CAD) and to establish a change in HRV before coronary artery bypass graft (CABG) surgery and during post-operative stay. The secondary aim of this study would be to associate this change in HRV with the patient’s clinical course. The validation component will test WHOOP’s HRV capabilities compared to the gold-standard Holter monitor.
